BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, April 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that its wholly-owned subsidiary, Aevi Genomic Medicine, LLC (“Cerecor”), has entered into an expanded agreement with Kyowa Kirin Co.,

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the industry’s only Decentralized Clinical Trial Operating System™, today announced a strategic partnership to enable enhanced decentralized clinical trial delivery.

Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform is

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.

- IONIS-PKK-L Rx met its primary and all secondary endpoints, including a mean reduction of up to 97% in HAE attacks compared to placebo

Diomics Corporation and Bonne Santé Group, Inc., through its Bonne Santé Natural Manufacturing division, today announced the execution of a strategic alliance agreement for the development, launch, and distribution of a line of Diocare™ products

– Transaction to advance Tempest’s targeted oncology pipeline – - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call today at 8:30 a.m. ET -